Merus (MRUS) Raised to “Hold” at BidaskClub

Share on StockTwits

BidaskClub upgraded shares of Merus (NASDAQ:MRUS) from a sell rating to a hold rating in a research note issued to investors on Saturday, BidAskClub reports.

Several other equities analysts also recently weighed in on the company. Royal Bank of Canada upgraded Merus from a sector perform rating to an outperform rating and increased their target price for the stock from $18.00 to $23.00 in a research report on Wednesday, April 3rd. ValuEngine downgraded Merus from a hold rating to a sell rating in a research report on Monday, February 4th. Berenberg Bank initiated coverage on Merus in a research report on Wednesday, March 27th. They set a buy rating and a $35.00 target price on the stock. Citigroup reduced their target price on Merus from $18.00 to $16.00 and set a neutral rating on the stock in a research report on Thursday, March 21st. Finally, Guggenheim initiated coverage on Merus in a research report on Friday. They set a buy rating and a $25.00 target price on the stock. Four research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $23.00.

NASDAQ MRUS opened at $16.45 on Friday. Merus has a twelve month low of $11.00 and a twelve month high of $26.74. The stock has a market cap of $349.21 million, a P/E ratio of -8.94 and a beta of -0.06.

A number of large investors have recently made changes to their positions in MRUS. Squarepoint Ops LLC increased its stake in Merus by 10.3% during the fourth quarter. Squarepoint Ops LLC now owns 11,800 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,100 shares during the last quarter. Geode Capital Management LLC increased its stake in Merus by 18.8% during the fourth quarter. Geode Capital Management LLC now owns 14,987 shares of the biotechnology company’s stock worth $209,000 after acquiring an additional 2,373 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Merus by 33.8% during the third quarter. JPMorgan Chase & Co. now owns 17,723 shares of the biotechnology company’s stock worth $350,000 after acquiring an additional 4,476 shares during the last quarter. Morgan Stanley increased its stake in Merus by 74.3% during the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock worth $1,415,000 after acquiring an additional 30,538 shares during the last quarter. Finally, Artal Group S.A. acquired a new stake in Merus during the fourth quarter worth about $2,886,000. Institutional investors own 53.06% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

See Also: What is the Difference Between Common Shares and Convertible Shares?

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: Snap Inc  VP Sells 8,100 Shares of Stock
Insider Selling: Snap Inc VP Sells 8,100 Shares of Stock
SenesTech Inc  CEO Buys $939,999.60 in Stock
SenesTech Inc CEO Buys $939,999.60 in Stock
Brokerages Anticipate BG Staffing Inc  to Post $0.30 EPS
Brokerages Anticipate BG Staffing Inc to Post $0.30 EPS
CoinFi 24-Hour Volume Tops $1,708.00
CoinFi 24-Hour Volume Tops $1,708.00
FLIP Hits Market Cap of $722,843.00
FLIP Hits Market Cap of $722,843.00
ChatCoin  24-Hour Volume Hits $396,693.00
ChatCoin 24-Hour Volume Hits $396,693.00


 
© 2006-2019 Zolmax.